Not every patient with primary myelofibrosis requires immediate intervention. A distinct subset presents in a low-burden state — without palpable splenomegaly, without constitutional or disease-related symptoms, and with blood counts that show no significant cytosis or cytopenia. This specific clinical picture carries its own management pathway.
The patient has no splenomegaly, no symptoms, and no cytosis or cytopenia. This combination identifies a lower-acuity presentation of primary myelofibrosis where the risk-benefit calculus of immediate therapy differs from more advanced disease states.
In this setting, the structured protocol addresses whether active treatment is warranted at all — with close surveillance for progression forming a central part of the approach. Eligibility for clinical investigation may also factor into the decision. The full criteria, decision points, and sequencing are detailed in the complete protocol.
DOI: 10.1182/blood.2022017423